Tides Medical Announces Artacent Launch and Tissue Bank Opening

Tides Medical has announced the launch of two amniotic membrane products, Artacent Flex and Artacent Wound. The two tissue products are the first to be processed in Tides Medical’s new, state-of-the art tissue processing facility located in Lafayette, La.

According to CEO Joe Spell, “We have been a successful private labeler of amniotic tissues for several years. This launch and the opening of our own tissue bank show our commitment to being a leader in the rapidly expanding market for donated amniotic tissue grafts.”

Artacent Flex is the original dual-layer amniotic graft designed specifically as a surgical barrier. Artacent Wound is a wound-specific, dual-layer amniotic graft designed for ease-of-use.

Concurrent with the launch, Tides Medical is beginning a large, multi-center, randomly controlled trial comparing Artacent Wound to standard-of-care treatment for diabetic and venous stasis ulcers.

 “This study is designed to be the most powerful study comparing amniotic membrane tissue therapies to current standard of care for the treatment of chronic wounds,” said Tides Vice President of Research Isabella Sledge, M.D., MPH.

Tides Medical, a privately funded medical technology firm in Lafayette, La., develops amniotic membrane technology.